Blood products maker CSL Ltd
(ASX:CSL) has posted a full year net profit of $1.05 billion and announced a share buy-back plan for $900 million of its shares.
The profit represents a fall of 8.1% from the year before, however based on constant currency prices CSL recorded a profit of $1.24 billion up 22% for the 12 months to 30 June.
CSL has also increased its final dividend 13% to 45 cents.
Managing Director Dr McNamee says the strong result was achieved despite currency headwinds, rigorous competition and global health healthcare reform.
Looking ahead Dr McNamee says operational profit growth is expected to be solid, largely underpinned by ongoing growth in demand for plasma therapies.
CSL has forecast a net profit after tax of between $980 million and $1 billion for the following financial year.
CSL reported a profit of $1.15 billion for the year to 30 June 2009.
